سیویلیکا را در شبکه های اجتماعی دنبال نمایید.

Exploring the efficacy of E 9447 Anti-cancer Agent binding to PARP1: a molecular dynamics simulation approach

Publish Year: 1403
Type: Conference paper
Language: English
View: 41

This Paper With 15 Page And PDF Format Ready To Download

Export:

Link to this Paper:

Document National Code:

BCSCD03_015

Index date: 17 March 2025

Exploring the efficacy of E 9447 Anti-cancer Agent binding to PARP1: a molecular dynamics simulation approach abstract

Poly polymerase 1, a protein of the PARP family, is involved in the cellular processes of DNA damage repair and apoptosis. Disabilities within the work of this protein can lead to distinctive illnesses, including cancer. E9447 is a novel PARP inhibitor with great potential as a cancer therapeutic. The point of this study is to investigate the interaction between E 9447 and the PARP 1 protein. In this study, a model of PARP1 protein was created with Modeller 7116 software. First, we chose a model of PARP 1 with a high degree of similarity to the Protein Data Bank, and introduction of this model into the simulation stage was based on energy. Simulation of its molecular dynamics was performed via GROMACS, after which its connection areas with E 9447 were ascertained by AutoDock 414 software. The stability of the root mean square deviation diagram and energy indicated that the three-dimensional structural model was stable and closely approximated natural PARP 1. Docking studies also showed that this protein has an attachment site

Exploring the efficacy of E 9447 Anti-cancer Agent binding to PARP1: a molecular dynamics simulation approach Keywords:

Exploring the efficacy of E 9447 Anti-cancer Agent binding to PARP1: a molecular dynamics simulation approach authors

Hamed Esmaeil Lashgarian

Associate Professor, Department of Medical Biotechnology, Faculty of Medicine, Lorestan University

Vahideh Assadollahi

Assistant Professor, Department of Tissue Engineering & Applied Cell Sciences, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.

Masumeh Jalalvand

Assistant Professor, Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.

Hamidreza Khodadadi

Assistant Professor, Hepatitis Research Center, Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

Leila Abkhooie

Assistant Professor, Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.

Amirmasoud Jalalvand

Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.